<DOC>
	<DOCNO>NCT00235209</DOCNO>
	<brief_summary>This randomize ( 1:1 ) , prospective , open label , multicenter , comparative study examine effectiveness Collagen-ORC Antimicrobial matrix , new wound dressing , venous leg ulcer .</brief_summary>
	<brief_title>A Study Evaluate Clinical Effectiveness Collagen-ORC Antimicrobial Matrix Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Be 18 year age old . Have evidence venous insufficiency document venous duplex scan impedance plethysmography within past 6 month . The study report must contain actual term `` venous incompetence '' must repeat . Have venous ulcer &gt; 3 &lt; 25 cm2 area , planimetry . Have venous ulcer open continuously &gt; 1 &lt; 18 month prior treatment . Have prescribe compression least 7 day immediately prior randomization , 14 day ( consecutive nonconsecutive ) . If female , subject must : postmenopausal without menses least 1 year , hysterectomy tubal ligation otherwise incapable pregnancy , negative serum Human Chorionic Gonadotropin ( HCG ) willing practice approve form birth control duration trial . Subject agree participate study , include study related procedure evaluation document agreement sign IRBapproved informed consent . Have designate study wound malleolus popliteal fossa . Have treat becaplermin ( PDGFBB ) topical recombinant therapy study wind within 30 day prior randomization . Have study wound treat , time , skin substitute autologous growth factor . Have surgical procedure treat venous arterial disease affect limb within past 90 day . Have evidence significant arterial insufficiency ( i.e . ankle brachial index &lt; 0.8 ) . Subjects ABI &gt; 1.0 must toe brachial index ( TBI ) &gt; 0.6 supine transcutaneous oxygen measurement affect leg distal wind &gt; 30mmHg . Have clinical evidence active infection wound site . Have evidence active vasculitis , cellulitis collagen vascular disease . Have participate clinical trial investigational agent within last 30 day . Have significant acute chronic disease ( i.e. , cardiovascular , pulmonary , gastrointestinal , hepatic , renal , neurological infectious disease ) adequately control medical treatment determine Investigator 's judgment . Have diabetes mellitus hemoglobin A1c &gt; 10 % . Have active skin disease , psoriasis , could impair ability ass study wound . Have allergy component dressing use study . Require concomitant use pentoxifylline clopidogrel bisulfate study . Have undergone enzymatic debridement study wind time 7 day prior first application study treatment . Have requirement use systemic steroid immunosuppressive cytotoxic compound period study receive lowdose steroid therapy 5 day within past year . Expect undergo hyperbaric oxygen therapy time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>